Gu Mi

1.1k citations

44 papers · 620 indexed · h-index 14

Impact in

Oncology top 10%
- Cancer Immunotherapy and Biomarkers
- Pancreatic and Hepatic Oncology Research
- Peptidase Inhibition and Analysis
Gastroenterology top 10%
- Gastrointestinal Tumor Research and Treatment

Papers in ⓘ

Oncology 30
- Cancer Immunotherapy and Biomarkers 13
- Colorectal Cancer Treatments and Studies 12
- Pancreatic and Hepatic Oncology Research 7
- CAR-T cell therapy research 5
Statistics and Probability 5
- Statistical Methods in Clinical Trials 5

Co-authors: Roy S. Herbst (14 shared papers)David Ferry (10 shared papers)Ian Chau (11 shared papers)Emiliano Calvo (11 shared papers)Hendrik‐Tobias Arkenau (10 shared papers)Nicolas Penel (7 shared papers)Jin Jin (5 shared papers)Johanna C. Bendell (12 shared papers)
Journals: Journal of Clinical Oncology (10 papers)Annals of Oncology (8 papers)Journal of Thoracic Oncology (3 papers)PLoS ONE (3 papers)Contemporary Clinical Trials (2 papers)
Partner nations: United States France Spain

In The Last Decade

Gu Mi

38 papers receiving 615 citations

Peers

Countries citing papers authored by Gu Mi

Since Specialization

Citations

This map shows the geographic impact of Gu Mi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gu Mi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gu Mi more than expected).

Fields of papers citing papers by Gu Mi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gu Mi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gu Mi. The network helps show where Gu Mi may publish in the future.

Co-authors

The 25 scholars most cited alongside Gu Mi, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Gu Mi Line = papers co-authored together Gu Mi links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 44 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open-Label, Phase I Trial (JVDF) The Oncologist ·Hendrik‐Tobias Arkenau, Juan Martín-Liberal, Emiliano Calvo, Nicolas Penel, Matthew Krebs, Roy S. Herbst, Richard A. Walgren, Ryan C. Widau, Gu Mi, Jin Jin, David Ferry, Ian Chau	2018	123
2	Ramucirumab and durvalumab for previously treated, advanced non–small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ) European Journal of Cancer ·Yung‐Jue Bang, Talia Golan, Laëtitia Dahan, Siqing Fu, Víctor Moreno, Keunchil Park, Ravit Geva, Filippo de Braud, Zev A. Wainberg, Martin Reck, Laura W. Goff, Naomi Laing, Gu Mi, Joana Oliveira, Heather Wasserstrom, Chia‐Chi Lin	2020	103
3	Phase 1 Expansion Cohort of Ramucirumab Plus Pembrolizumab in Advanced Treatment-Naive NSCLC Journal of Thoracic Oncology ·Roy S. Herbst, Hendrik Tobias Arkenau, Johanna C. Bendell, Edward Arrowsmith, Martin Wermke, A. Segado Soriano, Nicolas Penel, Rafael Santana-Dávila, Helge Bischoff, Ian Chau, Gu Mi, Hong Wang, Erik Rasmussen, David Ferry, Bo H. Chao, Luis Paz‐Ares	2020	44
4	A phase 1 study of ramucirumab (R) plus pembrolizumab (P) in patients (pts) with advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, non-small cell lung cancer (NSCLC), or urothelial carcinoma (UC): Phase 1a results. Journal of Clinical Oncology ·Roy S. Herbst, Johanna C. Bendell, Nicolás Isambert, Emiliano Calvo, Rafael Santana-Dávila, Philippe A. Cassier, José Luis Perez‐Gracia, Jing Yang, Jessicca Rege, David Ferry, Gu Mi, Ian Chau	2016	27
5	Ramucirumab (Ram) and durvalumab (Durva) treatment of metastatic non-small cell lung cancer (NSCLC), gastric/gastroesophageal junction (G/GEJ) adenocarcinoma, and hepatocellular carcinoma (HCC) following progression on systemic treatment(s). Journal of Clinical Oncology ·Yung‐Jue Bang, Talia Golan, Chia‐Chi Lin, Laëtitia Dahan, Siqing Fu, Víctor Moreno, Ravit Geva, Martin Reck, Heather Wasserstrom, Gu Mi, Naomi Laing, Laura W. Goff	2019	26
6	Interim safety and clinical activity in patients (pts) with advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma from a multicohort phase 1 study of ramucirumab (R) plus pembrolizumab (P). Journal of Clinical Oncology ·Ian Chau, Johanna C. Bendell, Emiliano Calvo, Rafael Santana-Dávila, Jordi Rodón, Nicolas Penel, Hendrik‐Tobias Arkenau, Jing Yang, Jessicca Rege, Gu Mi, David Ferry, Roy S. Herbst, Charles S. Fuchs	2017	24
7	Length Bias Correction in Gene Ontology Enrichment Analysis Using Logistic Regression PLoS ONE ·Gu Mi, Yanming Di, Sarah Emerson, Jason S. Cumbie, Jeff H. Chang	2012	23
8	Ramucirumab in Combination with Pembrolizumab in Treatment-Naïve Advanced Gastric or GEJ Adenocarcinoma: Safety and Antitumor Activity from the Phase 1a/b JVDF Trial Cancers ·Ian Chau, Nicolas Penel, Andres O. Soriano, Hendrik‐Tobias Arkenau, Jennifer L. Cultrera, Rafael Santana-Dávila, Emiliano Calvo, Christophe Le Tourneau, Lars Zender, Johanna C. Bendell, Gu Mi, Ling Gao, Samuel McNeely, Joana Oliveira, David Ferry, Roy S. Herbst, Charles S. Fuchs	2020	22
9	A multicohort phase I study of ramucirumab (R) plus pembrolizumab (P): Interim safety and clinical activity in patients with urothelial carcinoma. Journal of Clinical Oncology ·Daniel P. Petrylak, Hendrik‐Tobias Arkenau, José Luis Perez‐Gracia, Matthew Krebs, Rafael Santana-Dávila, Jing Yang, Jessicca Rege, Gu Mi, David Ferry, Roy S. Herbst	2017	22
10	A phase I dose escalation (DE) study of ERK inhibitor, LY3214996, in advanced (adv) cancer (CA) patients (pts). Journal of Clinical Oncology ·Shubham Pant, Johanna C. Bendell, Ryan J. Sullivan, Geoffrey I. Shapiro, Michael Millward, Gu Mi, Eunice Yuen, Melinda D. Willard, Dan Wang, Sajan Joseph, William T. McMillen, Shripad V. Bhagwat, Ramón V. Tiu, Manish R. Patel	2019	19
11	Interim safety and clinical activity in patients (pts) with locally advanced and unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma from a multicohort phase I study of ramucirumab (R) plus durvalumab (D). Journal of Clinical Oncology ·Yung‐Jue Bang, Talia Golan, Chia‐Chi Lin, Yoon‐Koo Kang, Zev A. Wainberg, Heather Wasserstrom, Jin Jin, Gu Mi, Samuel McNeely, Naomi Laing, Laura W. Goff, Siqing Fu	2018	19
12	Safety and antitumor activity of ramucirumab plus pembrolizumab in treatment naïve advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: Preliminary results from a multi-disease phase I study (JVDF). Journal of Clinical Oncology ·Ian Chau, Nicolas Penel, Hendrik‐Tobias Arkenau, Rafael Santana-Dávila, Emiliano Calvo, Andres O. Soriano, Gu Mi, Jin Jin, David Ferry, Roy S. Herbst, Charles S. Fuchs	2018	19
13	Goodness-of-Fit Tests and Model Diagnostics for Negative Binomial Regression of RNA Sequencing Data PLoS ONE ·Gu Mi, Yanming Di, Daniel W. Schafer	2015	15
14	Ramucirumab (R) plus pembrolizumab (P) in treatment naive and previously treated advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: A multi-disease phase I study. Journal of Clinical Oncology ·Ian Chau, Johanna C. Bendell, Emiliano Calvo, Rafael Santana-Dávila, Hendrik‐Tobias Arkenau, Gu Mi, Jin Jin, Jessicca Rege, David Ferry, Roy S. Herbst, Charles S. Fuchs	2017	15
15	Extreme short-term prediction of ship motion based on chaotic theory and RBF neural network Chuanbo lixue ·Gu Mi	2013	12
16	Previously treated advanced NSCLC cohort from a multi-disease phase 1 study of ramucirumab (R) plus pembrolizumab (P): Efficacy and safety data Annals of Oncology ·Roy S. Herbst, Juan Martín-Liberal, Emiliano Calvo, Nicolás Isambert, Johanna C. Bendell, Philippe A. Cassier, Jong‐Youl Jin, Gu Mi, Jessicca Rege, Luis Paz‐Ares	2017	12
17	Interim safety and clinical activity in patients with advanced NSCLC from a multi-cohort phase 1 study of ramucirumab (R) plus pembrolizumab (P) Annals of Oncology ·Roy S. Herbst, Juan Martín-Liberal, Emiliano Calvo, Nicolás Isambert, Johanna C. Bendell, Philippe A. Cassier, José Luis Perez‐Gracia, Jyun-Yan Yang, Jessicca Rege, Gu Mi, D. Ferry, Luis Paz‐Ares	2016	11
18	EGFR Gene Copy Number by FISH May Predict Outcome of Necitumumab in Squamous Lung Carcinomas: Analysis from the SQUIRE Study Journal of Thoracic Oncology ·Carlo Genova, Mark A. Socinski, Rebecca R. Hozak, Gu Mi, Raffael Kurek, Javad Shahidi, Luis Paz‐Ares, Nick Thatcher, Christopher J. Rivard, Marileila Varella- Garcia, Fred R. Hirsch	2017	10
19	A first-in-human study of CD123 NK cell engager SAR443579 in relapsed or refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia, or high-risk myelodysplasia. Journal of Clinical Oncology ·Anthony S. Stein, Mojca Jongen‐Lavrencic, Sylvain Garciaz, Gerwin Huls, Abhishek Maiti, Nicolas Boissel, Stéphane de Botton, Shaun Fleming, C. Michel Zwaan, David C. de Leeuw, Pinkal Desai, Martha Arellano, David Avigan, Saskia Langemeijer, Kyle A. Jensen, Timothy R. Wagenaar, Gu Mi, Giovanni Abbadessa, Ashish Bajel	2023	10
20	Phase 1 study of ramucirumab (R) plus durvalumab (D) in patients (pts) with locally advanced and unresectable or metastatic gastrointestinal or thoracic malignancies (NCT02572687); Phase 1a results Annals of Oncology ·C.-C. Lin, Talia Golan, J. Corral, Vicente Moreno, Hyun Cheol Chung, Heather Wasserstrom, Jing Yang, Gu Mi, Y. Bang	2016	8

About Gu Mi

Gu Mi is a scholar working on Oncology, Statistics and Probability, Pulmonary and Respiratory Medicine, Hematology and Biotechnology, having authored 44 papers that have together received 620 indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (13 papers), Colorectal Cancer Treatments and Studies (12 papers), Gastric Cancer Management and Outcomes (10 papers), Pancreatic and Hepatic Oncology Research (7 papers), CAR-T cell therapy research (5 papers), Statistical Methods in Clinical Trials (5 papers), Immune Cell Function and Interaction (4 papers) and Lung Cancer Treatments and Mutations (4 papers). The work is most often cited by research in Oncology (440 citations), Gastroenterology (59 citations), Hepatology (77 citations), Pulmonary and Respiratory Medicine (240 citations) and Immunology (102 citations). Gu Mi has collaborated with scholars based in United States, France and Spain. Frequent co-authors include Roy S. Herbst, David Ferry, Ian Chau, Emiliano Calvo, Hendrik‐Tobias Arkenau, Nicolas Penel, Jin Jin, Johanna C. Bendell, Rafael Santana-Dávila and Matthew Krebs. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Journal of Thoracic Oncology, PLoS ONE and Contemporary Clinical Trials.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact